DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Venlafaxine hydrochlorideis the generic ingredient in three branded drugs marketed by Upjohn, Anchen Pharms, Annora Pharma, Aurobindo Pharma Ltd, Dr Reddys Labs Ltd, Intellipharmaceutics, Inventia Hlthcare, Macleods Pharms Ltd, Mylan, Orchid Hlthcare, Teva, Torrent Pharms Llc, Valeant Pharms North, Wockhardt, Zydus Pharms Usa Inc, Cadila Pharms Ltd, Dexcel Pharma, Nostrum Labs Inc, Osmotica Pharm, Sun Pharm, Wyeth Pharms Inc, Alembic Pharms Ltd, Amneal Pharms, Aurobindo Pharma, Fosun Pharma, Heritage Pharms Inc, Pliva Hrvatska Doo, Prinston Inc, Sun Pharm Inds Inc, Yaopharma Co Ltd, and Zydus Pharms Usa, and is included in thirty-five NDAs. Additional information is available in the individual branded drug profile pages.
There are seventy-one drug master file entries for venlafaxine hydrochloride. Fifty-five suppliers are listed for this compound. There are two tentative approvals for this compound.
Summary for venlafaxine hydrochloride
|Drug Master File Entries:||71|
|Suppliers / Packagers:||55|
|Bulk Api Vendors:||108|
|Formulation / Manufacturing:||see details|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for venlafaxine hydrochloride|
|DailyMed Link:||venlafaxine hydrochloride at DailyMed|
Recent Clinical Trials for venlafaxine hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
|Online PsychoTherapy Clinic||N/A|
|Medical University of South Carolina||Phase 2/Phase 3|
Generic filers with tentative approvals for VENLAFAXINE HYDROCHLORIDE
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for venlafaxine hydrochloride
|Drug Class||Serotonin and Norepinephrine Reuptake Inhibitor |
|Mechanism of Action||Norepinephrine Uptake Inhibitors |
Serotonin Uptake Inhibitors
Medical Subject Heading (MeSH) Categories for venlafaxine hydrochloride
Paragraph IV (Patent) Challenges for VENLAFAXINE HYDROCHLORIDE
|VENLAFAXINE HYDROCHLORIDE||TABLET, EXTENDED RELEASE;ORAL||venlafaxine hydrochloride||022104||2011-01-10|
|VENLAFAXINE HYDROCHLORIDE||TABLET, EXTENDED RELEASE;ORAL||venlafaxine hydrochloride||022104||2009-02-12|
|EFFEXOR XR||CAPSULE, EXTENDED RELEASE;ORAL||venlafaxine hydrochloride||020699||2007-05-03|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.